Real-world safety data from patients with rheumatic diseases treated with CT-P13, an infliximab biosimilar: an interim analysis from an observational study

類似資料

• Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST)
  著者:: Taylor, PC, 等
  出版事項: (2021)
• Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
  著者:: Bente Glintborg, 等
  出版事項: (2022-11-01)
• Infusion reaction to infliximab biosimilar after transitioning from infliximab
  著者:: Reem Kashlan, MPH, 等
  出版事項: (2021-02-01)
• Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics
  著者:: Mohammed M. Kamil, 等
  出版事項: (2023-01-01)
• A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease
  著者:: Shin Kashima, 等
  出版事項: (2022-05-01)